Related Experiment Videos
Activation of pain by sumatriptan
David M Coulter1, J L M Passier, David W J Clark
1Intensive Medicines Monitoring Programme, Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand.
Headache
|September 27, 2003
Summary
Sumatriptan may worsen or trigger pain at inflammation sites, particularly with subcutaneous use. This pain activation could be a common effect of selective serotonergic agonists used for migraine treatment.
Area of Science:
- Pharmacology
- Clinical Medicine
- Adverse Drug Reactions
Background:
- Sumatriptan is a widely used medication for migraine treatment.
- Selective serotonergic agonists target specific serotonin receptors.
Observation:
- Case reports from the Netherlands and New Zealand were analyzed.
- Data was collected through spontaneous reporting and cohort studies.
- Potential mechanisms for sumatriptan-induced pain were explored.
Findings:
- Sumatriptan was associated with pain activation/aggravation in 13 cases post-injury and 8 with inflammatory diseases.
- Subcutaneous sumatriptan showed a higher incidence of this reaction compared to oral formulations.
- Rechallenge was positive in most patients, indicating a drug-related effect.
Implications:
- A strong association exists between sumatriptan use and pain at inflammatory sites.
- Pain activation may be a class effect of selective serotonergic agonists.
- This finding warrants consideration in clinical practice, especially for patients with inflammatory conditions.